As of 2025-07-14, the Intrinsic Value of Lotus Pharmaceutical Co Ltd (1795.TW) is 314.32 TWD. This 1795.TW valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 215.00 TWD, the upside of Lotus Pharmaceutical Co Ltd is 46.20%.
The range of the Intrinsic Value is 242.76 - 444.15 TWD
Based on its market price of 215.00 TWD and our intrinsic valuation, Lotus Pharmaceutical Co Ltd (1795.TW) is undervalued by 46.20%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 242.76 - 444.15 | 314.32 | 46.2% |
| DCF (Growth 10y) | 309.95 - 556.65 | 397.91 | 85.1% |
| DCF (EBITDA 5y) | 275.74 - 338.62 | 311.35 | 44.8% |
| DCF (EBITDA 10y) | 346.81 - 451.35 | 401.14 | 86.6% |
| Fair Value | 513.96 - 513.96 | 513.96 | 139.05% |
| P/E | 276.49 - 518.74 | 359.73 | 67.3% |
| EV/EBITDA | 181.31 - 276.68 | 245.01 | 14.0% |
| EPV | 147.30 - 224.25 | 185.77 | -13.6% |
| DDM - Stable | 181.07 - 428.04 | 304.56 | 41.7% |
| DDM - Multi | 223.95 - 429.39 | 296.16 | 37.8% |
| Market Cap (mil) | 57,149.15 |
| Beta | 0.51 |
| Outstanding shares (mil) | 265.81 |
| Enterprise Value (mil) | 63,943.57 |
| Market risk premium | 5.98% |
| Cost of Equity | 6.64% |
| Cost of Debt | 4.25% |
| WACC | 6.00% |